HK1043051B - 控釋安非他酮配方 - Google Patents

控釋安非他酮配方

Info

Publication number
HK1043051B
HK1043051B HK02104353.1A HK02104353A HK1043051B HK 1043051 B HK1043051 B HK 1043051B HK 02104353 A HK02104353 A HK 02104353A HK 1043051 B HK1043051 B HK 1043051B
Authority
HK
Hong Kong
Prior art keywords
controlled release
coating
bupropion hydrochloride
release bupropion
pellet
Prior art date
Application number
HK02104353.1A
Other languages
English (en)
Other versions
HK1043051A1 (en
Inventor
Chen Chih-Ming
Xie Jianbo
Jan Steve
Original Assignee
Andrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals Inc filed Critical Andrx Pharmaceuticals Inc
Publication of HK1043051A1 publication Critical patent/HK1043051A1/xx
Publication of HK1043051B publication Critical patent/HK1043051B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
HK02104353.1A 1999-02-26 2002-06-11 控釋安非他酮配方 HK1043051B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/259,133 US6210716B1 (en) 1999-02-26 1999-02-26 Controlled release bupropion formulation
PCT/US2000/004636 WO2000050010A1 (en) 1999-02-26 2000-02-24 Controlled release bupropion formulation

Publications (2)

Publication Number Publication Date
HK1043051A1 HK1043051A1 (en) 2002-09-06
HK1043051B true HK1043051B (zh) 2004-02-06

Family

ID=22983669

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02104353.1A HK1043051B (zh) 1999-02-26 2002-06-11 控釋安非他酮配方

Country Status (10)

Country Link
US (1) US6210716B1 (zh)
EP (1) EP1162951B1 (zh)
JP (1) JP2002537319A (zh)
AT (1) ATE243026T1 (zh)
AU (1) AU757915B2 (zh)
CA (1) CA2363168A1 (zh)
DE (1) DE60003396T2 (zh)
ES (1) ES2200832T3 (zh)
HK (1) HK1043051B (zh)
WO (1) WO2000050010A1 (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
WO2001080824A2 (en) * 2000-04-19 2001-11-01 Eurand America, Inc. Dual mechanism timed release dosage forms for low dose drugs
AU2001230490A1 (en) * 2000-12-01 2002-06-11 Arun Shriniwas Gosavi Pharmaceutical formulation
EP1357898A4 (en) * 2001-02-08 2005-07-13 Andrx Pharmaceuticals Inc ORAL DOSAGE FORM WITH ENHANCED REGULATED RELEASE
ITMI20011457A1 (it) * 2001-07-09 2003-01-09 Valpharma Sa Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
EP2301537A1 (en) * 2002-05-17 2011-03-30 Duke University Zonisamide for the treatment of obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
SI2316456T1 (sl) * 2003-04-29 2017-10-30 Orexigen Therapeutics, Inc. Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
ATE454138T1 (de) * 2003-08-08 2010-01-15 Biovail Lab Int Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005070461A2 (en) * 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
CN1968692A (zh) * 2004-05-03 2007-05-23 杜克大学 影响体重减轻的组合物
US8586085B2 (en) * 2004-11-08 2013-11-19 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion
US20060099262A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
US20060099261A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
KR100670798B1 (ko) 2004-12-17 2007-01-17 한국전자통신연구원 데이터베이스 캐시 시스템
WO2007002597A2 (en) * 2005-06-27 2007-01-04 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
EP2135603B1 (en) * 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
PT1954241E (pt) * 2005-11-28 2012-06-01 Orexigen Therapeutics Inc Formulação de zonisamida de libertação sustentada
WO2007117314A2 (en) * 2005-12-06 2007-10-18 Biokey, Inc. Bupropion controlled release formulations and methods of making
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR101735466B1 (ko) 2006-11-09 2017-05-15 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR20150082689A (ko) * 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US9358213B2 (en) * 2007-04-20 2016-06-07 Wockhardt Limited Pharmaceutical compositions of duloxetine
CA2725930A1 (en) * 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20100239681A1 (en) * 2009-03-20 2010-09-23 Biokey, Inc. Controlled Release Particulates Containing Water-Insoluble Drug
CN102724878A (zh) * 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
DK3730132T3 (da) 2012-06-06 2022-08-08 Nalpropion Pharmaceuticals Llc Sammensætning til anvendelse ved en fremgangsmåde til behandling af overvægt og obesitas hos patienter med høj kardiovaskulær risiko
JP6392355B2 (ja) 2013-09-13 2018-09-19 アール．ピー．シェーラー テクノロジーズ、エルエルシー ペレット包含錠剤
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2011587A (en) 1934-03-24 1935-08-20 Kelp Ol Lab Inc Coating for medical compound
US2987445A (en) 1958-10-10 1961-06-06 Rohm & Haas Drug composition
GB906331A (en) 1959-12-21 1962-09-19 Kefalas As Appetite-reducing compositions comprising phenylamino propane derivatives
GB972128A (en) 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
BE759838A (fr) 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
US3773920A (en) 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
US4096238A (en) 1974-12-23 1978-06-20 Alza Corporation Method for administering drug to the gastrointestinal tract
US4014334A (en) 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4016880A (en) 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4309405A (en) 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
SE8100276L (sv) 1980-01-21 1981-07-22 Wellcome Found Farmaceutiskt aktiv komposition omfattande ketoner och heterocykliska foreningar
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4439194A (en) 1981-09-08 1984-03-27 Merck & Co., Inc. Water and drug delivery system for suppository use
US4393078A (en) 1982-03-15 1983-07-12 Burroughs Wellcome Co. Bupropion and ethanol
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4557925A (en) 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
DK58983D0 (da) * 1983-02-11 1983-02-11 Leo Pharm Prod Ltd Farmaceutisk praeparat
US4539198A (en) 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
USRE33994E (en) 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
US4507323A (en) 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4935429A (en) 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
JPH07552B2 (ja) * 1987-11-06 1995-01-11 田辺製薬株式会社 持効性製剤
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5098715A (en) 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer

Also Published As

Publication number Publication date
ATE243026T1 (de) 2003-07-15
AU3005800A (en) 2000-09-14
US6210716B1 (en) 2001-04-03
HK1043051A1 (en) 2002-09-06
DE60003396T2 (de) 2004-04-22
EP1162951B1 (en) 2003-06-18
JP2002537319A (ja) 2002-11-05
EP1162951A4 (en) 2002-09-04
DE60003396D1 (de) 2003-07-24
CA2363168A1 (en) 2000-08-31
ES2200832T3 (es) 2004-03-16
EP1162951A1 (en) 2001-12-19
AU757915B2 (en) 2003-03-13
WO2000050010A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
HK1043051A1 (en) Controlled release bupropion formulation
PL356962A1 (en) Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
EP0835102A4 (en) FORMULATION WITH A PREFORMED OPENING FOR CONTROLLED RELEASE
CA2351814A1 (en) Taste masked pharmaceutical particles
HK1044480A1 (en) New omeprazole and (s)-omeprazole formulation.
KR920702618A (ko) 약제학적 제형
ATE376414T1 (de) Pellet formulierung mit gesteuerter freisetzung
CA2046739A1 (en) Coated solid medicament form having releasability in large intestine
IL142474A0 (en) Pharmaceutical formulation comprising omeprazole
CA2306103A1 (en) Novel once-a-day controlled release sulfonylurea formulation
DK0977557T3 (da) Pelletpræparat til behandling af tarmkanalen
CA2315329A1 (en) Improved hmg coa reductase inhibitor extended release formulation
NZ527585A (en) Tablets quickly disintegrated in oral cavity
WO2002026210A3 (en) Proton pump inhibitor formulation
NZ509028A (en) Stable extended release oral dosage composition comprising a pseudoephedrine-containing core, the core being uniformly covered with a desloratadine-containing film
ATE239454T1 (de) Orale morphinzubereitung in teilchenform
SE9703206D0 (sv) Oral komposition innehållande olanzapin och förfarande för framställning därav
GEP20043198B (en) Extended Release Formulation
CA2290531A1 (en) Pharmaceutical formulation of omeprazole
GB9025372D0 (en) Pharmaceutical dosage forms
SE8602722D0 (sv) Hallbara administreringsformer
WO2002024174A3 (en) Sustained release composition containing clarithromycin
ES2130081A1 (es) Comprimido de maleato de trimebutina con recubrimiento laminar.
BG104757A (en) Pellets having a core coated with a lipid lowering agent and a polymer
CA2433915A1 (en) Improved controlled release oral dosage form

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080224